1. Home
  2. ZS vs UTHR Comparison

ZS vs UTHR Comparison

Compare ZS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zscaler Inc.

ZS

Zscaler Inc.

N/A

Current Price

$176.06

Market Cap

24.2B

Sector

Technology

ML Signal

N/A

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

N/A

Current Price

$513.36

Market Cap

23.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZS
UTHR
Founded
2007
1996
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2B
23.1B
IPO Year
2018
1999

Fundamental Metrics

Financial Performance
Metric
ZS
UTHR
Price
$176.06
$513.36
Analyst Decision
Buy
Buy
Analyst Count
38
14
Target Price
$264.94
$567.57
AVG Volume (30 Days)
2.2M
445.1K
Earning Date
05-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
30.77
13.07
EPS
N/A
13.07
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$27.83
$6.39
Revenue Next Year
$19.67
$14.18
P/E Ratio
N/A
$39.26
Revenue Growth
N/A
2.38
52 Week Low
$114.63
$302.19
52 Week High
$336.99
$609.35

Technical Indicators

Market Signals
Indicator
ZS
UTHR
Relative Strength Index (RSI) 57.71 44.14
Support Level $139.28 $464.92
Resistance Level $179.90 $516.36
Average True Range (ATR) 7.74 15.53
MACD -0.34 0.68
Stochastic Oscillator 58.68 43.90

Price Performance

Historical Comparison
ZS
UTHR

About ZS Zscaler Inc.

Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: